深度解析医学证据,lxfs.net为你支撑决策
2026年美国肝病研究学会年会(The Liver Meeting 2026,AASLD 2026)于11月5日-9日在美国科罗拉多州丹佛市隆重召开。作为全球肝病领域一年一度的顶级学术盛会,本次大会汇集国内外专家学者,聚焦肝病前沿热点,分享多项重磅原创研究成果。
首都医科大学附属北京友谊医院尤红教授团队两项围绕肝纤维化机制与靶向治疗的研究精彩亮相大会。研究分别证实,肝星状细胞来源的 THBS2 通过调控SPP1推动肝纤维化进展,联合靶向 THBS2–SPP1 轴可产生协同抗纤维化效应;HSC 特异性 MFAP-4 可稳定细胞外基质、激活 Rho-ROCK 信号通路促进肝纤维化,抑制 MFAP-4 能够有效减轻纤维化病变。两项研究为肝纤维化的靶向新药研发提供了全新的潜在靶点与理论依据。肝胆相照平台特整理该项研究核心内容,供广大临床同道参考学习。
一 0093 HSC 驱动的肝纤维化中的 THBS2–SPP1 轴:抗纤维化治疗的协同目标
THE THBS2–SPP1 AXIS IN HSC-DRIVEN LIVER FIBROGENESIS: A SYNERGISTIC TARGET FOR ANTIFIBROTIC THERAPY
作者:Hong Li¹, Ning Zhang¹, Wen Zhang¹, Wenyue Wu¹, Ziyan Pan¹, Haodong Ma¹, Caihong Wang¹, Ruoyu Gao¹, Zhi Chen¹, Qiushuang Ji¹, Xunzhen Yan¹, Aiting Yang¹, Aiting Yang¹, Wei Chen¹, Hong You¹
1 Beijing Friendship Hospital, Capital Medical University
背景
血小板反应蛋白-2(THBS2)在纤维化肝脏中显著上调,且其水平与纤维化分期相关,并不受病因影响。本研究旨在阐明肝星状细胞(HSC)来源的THBS2在肝纤维化进展中的作用及其潜在机制。
Background:Thrombospondin-2 (THBS2) is markedly upregulated in fibrotic livers and correlates with fibrosis stage independently of etiology. This study aimed to elucidate the role and underlying mechanisms of hepatic stellate cell (HSC)-derived THBS2 in the progression of liver fibrosis.
方法
构建HSC特异性 Thbs2 敲除小鼠(Thbs2ΔHSC)和人源 THBS2 敲入小鼠(hTHBS2KI HSC)。通过注射四氯化碳(CCl₄)或胆管结扎(BDL)诱导肝纤维化。采用双重靶向策略研究THBS2–SPP1轴的功能作用:通过腹腔注射抗小鼠SPP1抗体(inVivoMAb)中和细胞外SPP1,同时利用AAV6-GFAP-shSpp1抑制细胞内SPP1。此外,研究筛选出一种THBS2特异性抑制剂,并将其与靶向SPP1的小分子联合使用,以评估双重抑制THBS2–SPP1对肝纤维化的治疗潜力。
Methods:HSC-specific Thbs2 knockout (Thbs2ΔHSC) and human THBS2 knock-in (hTHBS2KI HSC) mice were generated. Liver fibrosis was induced by carbon tetrachloride (CCl₄) injection or bile duct ligation (BDL). The functional role of the THBS2–SPP1 axis was investigated using a dual targeting strategy: extracellular SPP1 was neutralized by intraperitoneal administration of an anti-mouse SPP1 antibody (inVivoMAb), while intracellular SPP1 was suppressed via AAV6-GFAP-shSpp1. Additionally, a THBS2-specific inhibitor was identified and combined with an SPP1-targeting small molecule to evaluate the therapeutic potential of dual THBS2–SPP1 inhibition in liver fibrosis.
结果
在CCl₄和BDL诱导的模型中,Thbs2ΔHSC小鼠的肝脏炎症和纤维化均明显减轻。相反,hTHBS2KI HSC小鼠的炎症和纤维化进展显著加重。机制方面,敲低HSC中的 Thbs2 明显抑制促纤维化介质SPP1的表达,而过表达THBS2则显著增加SPP1的表达和分泌;体外实验也一致验证了这些发现。此外,分子相互作用分析显示,THBS2可与SPP1直接相互作用。重要的是,在CCl₄处理的hTHBS2KI HSC小鼠中,给予抗SPP1中和抗体或通过AAV6-GFAP-shSpp1介导基因沉默,均显著减轻了纤维化进展,表明SPP1在THBS2介导的肝纤维化过程中发挥重要作用。
此外,研究通过整合虚拟药物筛选和表面等离子体共振(SPR)验证,筛选出一种新型THBS2抑制剂。药效学分析显示,该化合物在CCl₄和3,5-二乙氧羰基-1,4-二氢可力丁(DDC)诱导的肝纤维化模型中均表现出显著的抗纤维化作用,并伴有明显的组织病理学改善。值得注意的是,在CCl₄处理的hTHBS2KI HSC小鼠中,联合靶向THBS2–SPP1轴产生了协同抗纤维化作用。
Results:Thbs2ΔHSC mice exhibited markedly attenuated hepatic inflammation and fibrosis in both CCl₄- and BDL-induced models. Conversely, hTHBS2KI HSC mice showed significantly aggravated inflammation and fibrotic progression. Mechanistically, Thbs2 knockdown in HSCs markedly suppressed the expression of the pro-fibrotic mediator SPP1, whereas THBS2 overexpression robustly increased both SPP1 expression and secretion—findings consistently validated in vitro. Moreover, molecular interaction analyses revealed that THBS2 directly interacts with SPP1. Importantly, both anti-SPP1 neutralizing antibody administration and AAV6-GFAP-shSpp1-mediated gene silencing significantly attenuated fibrotic progression in CCl₄treated hTHBS2KI HSC mice, indicating that SPP1 plays an essential role in THBS2-mediated liver fibrogenesis. Furthermore, a novel THBS2 inhibitor was identified through integrated virtual drug screening combined with surface plasmon resonance (SPR) validation. Pharmacodynamic analyses demonstrated that this compound exerted significant antifibrotic effects in both CCl₄- and 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-induced liver fibrosis models, accompanied by marked histopathological improvement. Notably, combined targeting of the THBS2–SPP1 axis produced synergistic anti-fibrotic effects in CCl₄treated hTHBS2KI HSC mice.
结论
研究结果表明,HSC来源的THBS2通过调控SPP1促进肝纤维化。协同靶向THBS2–SPP1轴是一种有前景的治疗策略,有望显著减轻肝纤维化。
Conclusion:Our findings demonstrate that HSC-derived THBS2 drives liver fibrogenesis through regulation of SPP1. Coordinated targeting of the THBS2–SPP1 axis represents a promising therapeutic strategy to substantially mitigate liver fibrosis.
二 3354 肝星状细胞特异性MFAP-4通过稳定细胞外基质并激活细胞内Rho-ROCK信号通路,促进肝纤维化
HEPATIC STELLATE CELL–SPECIFIC MFAP-4 ENHANCES LIVER FIBROSIS BY STABILIZING THE EXTRACELLULAR MATRIX AND ACTIVATING INTRACELLULAR RHO-ROCK SIGNALING
作者:Wenyue Wu¹, Wen Zhang¹, Hong Li¹, Haodong Ma¹, Ziyan Pan¹, Caihong Wang¹, Yameng Sun¹, Ning Zhang¹, Xuzhen Yan¹, Aiting Yang¹, Wei Chen¹, Hong You¹
1 Beijing Friendship Hospital, Capital Medical University
研究背景
微原纤维相关蛋白4(MFAP-4)属于纤维蛋白原相关蛋白超家族,是细胞外基质(ECM)的重要组成部分。然而,其在肝纤维化发病机制中的作用仍未得到充分明确。
Background:Microfibril-associated protein 4 (MFAP-4) is a member of the fibrinogen-related protein superfamily and a key component of the extracellular matrix (ECM). However, its role in the pathogenesis of liver fibrosis remains poorly defined.
研究方法
研究使用不同病因肝硬化患者的肝活检样本及多种肝纤维化小鼠模型,检测MFAP-4的表达和细胞定位。为探究MFAP-4在体内肝星状细胞(HSC)中的作用,在CCl₄诱导的肝纤维化模型中,使用AAV6-Lrat-Cre在Mfap4fl/fl小鼠中诱导HSC特异性删除Mfap4。
体外实验使用MFAP-4过表达或敲低的LX-2细胞评估HSC活化,并通过3D ECM培养、胶原凝胶收缩实验和荧光评估其功能效应。通过免疫沉淀-质谱分析(IP-MS)鉴定潜在的MFAP-4相互作用蛋白及相关通路,并使用通路抑制剂进一步验证。研究还在CCl₄和BDL模型中通过AAV6介导的Mfap4 shRNA递送,并结合虚拟筛选得到的小分子MFAP-4抑制剂,检测抑制MFAP-4的抗纤维化潜力。
Methods:Liver biopsy samples from cirrhotic patients of different etiologies and several mouse models of liver fibrosis were used to examine MFAP-4 expression and cellular localization. To explore its role in hepatic stellate cells (HSCs) in vivo, HSC-specific deletion of Mfap4 was induced in Mfap4fl/fl mice using AAV6-Lrat-Cre in the CCl₄ fibrosis model. In vitro, LX-2 cells with MFAP-4 overexpression or knockdown were used to assess HSC activation, while 3D ECM culture, collagen gel contraction, and immunofluorescence were performed to evaluate its functional effects. Potential MFAP-4 interacting proteins and related pathways were identified by IP-MS and further verified using pathway inhibitors. The antifibrotic potential of MFAP-4 inhibition was tested using AAV6-mediated Mfap4 shRNA delivery in CCl₄ and BDL models, together with a small-molecule MFAP-4 inhibitor identified through virtual screening.
研究结果
MFAP-4主要富集于活化的HSC中,并且在人和小鼠的进展期肝纤维化中均显著上调。在CCl₄处理后,Mfap4ΔHSC小鼠中的HSC特异性Mfap4抑制显著减轻了肝纤维化和肝内炎症。机制方面,MFAP-4促进I型胶原和弹性蛋白沉积,并增强凝胶收缩,从而促进ECM硬度介导的HSC活化。
IP-MS分析显示,MFAP-4可与Rho-ROCK通路的多个组成部分相互作用;抑制该通路可逆转MFAP-4诱导的HSC活化和3D ECM中的凝胶收缩。值得注意的是,通过AAV6-GFAP-shMfap4或AAV6-U6-shMfap4选择性敲低Mfap4,均显著延缓了CCl₄和BDL模型中的肝纤维化。选择性小分子MFAP-4抑制剂BJFSH102通过破坏MFAP-4与弹性蛋白和I型胶原的相互作用,减轻了CCl₄模型中的肝纤维化。
Results:MFAP-4 was predominantly enriched in activated HSCs and significantly upregulated in advanced liver fibrosis in both humans and mice. HSC-specific suppression of Mfap4 in Mfap4ΔHSC mice markedly attenuated fibrosis and intrahepatic inflammation after CCl₄ treatment. Mechanistically, MFAP-4 promoted Collagen I and Elastin deposition, as well as gel contraction, thereby enhancing ECM stiffness-mediated HSC activation. IP-MS analysis showed that MFAP-4 interacts with multiple components of the Rho-ROCK pathway; inhibition of this pathway reversed MFAP-4-induced HSCs activation and gel contraction in the 3D ECM. Notably, selective knockdown of Mfap4 by either AAV6-GFAP-shMfap4 or AAV6-U6-shMfap4 significantly retarded liver fibrosis in CCl₄ and BDL models. BJFSH102, a selective small-molecule MFAP-4 inhibitor, ameliorated liver fibrosis by disrupting MFAP-4 interactions with Elastin and Collagen I in CCl₄ models.
研究结论
研究结果表明,HSC来源的MFAP-4通过促进弹性蛋白和I型胶原沉积,并增强ECM硬度介导的HSC活化,推动肝纤维化发生。选择性抑制HSC来源的MFAP-4可有效减轻纤维化,是一种有前景的肝纤维化治疗策略。
Conclusion:Our findings indicate that HSC-derived MFAP-4 drives liver fibrogenesis by promoting Elastin and Collagen I deposition and reinforcing ECM stiffness-mediated HSC activation. Selective inhibition of HSC-derived MFAP-4 effectively attenuates fibrosis, representing a promising therapeutic strategy for liver fibrosi.
